Compare Standard Lithium Ltd (SLI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs BIO-TECHNE Corp — how do they compare? Standard Lithium Ltd trades at $1.61 (market cap $409.74M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 27.7× Standard Lithium Ltd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and BIO-TECHNE Corp for 63 Days on average.
| SLI | TECH | |
|---|---|---|
Market Cap | $409.74M | $11.37B |
Volume | 1,266,140 | 3,153,511 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $72.61 |
52-Week Low | $1.61 | $43.31 |
Typical Hold Time | 23 Days | 63 Days |
Enterprise Value | $272.66M | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported no revenue in 2025 and negative net income of -$48.40M, though recent quarters show improving EPS trends with two consecutive beats. Key developments include progress toward a final investment decision for the South West Arkansas lithium project by end-2026 and new customer offtake agreements.
The stock presents high-risk, high-reward potential with 100% analyst buy ratings and a $3.83 consensus price target offering 132% upside. However, significant execution risks remain as the company transitions to commercial production, with negative cash flow from operations and substantial capital requirements ahead.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
